Blackstone Invests $125 Million in Soon-Shiong’s NantPharma

By Deborah Crowe Tuesday, July 24, 2012

Patrick Soon-Shiong’s NantWorks LLC on Tuesday said that New York investment firm Blackstone has invested $125 million in one of its health care companies, NantPharma.

It’s the first time NantWorks, the billionaire’s West L.A. holding company, has accepted a large outside investment into one of its start-ups. Soon-Shiong told the Business Journal that two Blackstone executives will bring their expertise in growing health care companies as new members of NantPharma’s board.

NantPharma, which is based in Los Angeles and operates four drug manufacturing and research facilities in other states, specializes in creating safer, more efficiently processed drug components and treatments for diseases ranging from hemophilia to immune system disorders. It employs 250 people, about 50 of them in Los Angeles.

“Our country must have absolutely reliable sources of blood plasma products,” Soon-Shiong said. “We must also enhance our capabilities to manufacture injectable and next generation drugs in America.”

NantWorks last week announced a joint venture with Malibu toymaker Jakks Pacific Inc. to create interactive toys. The toys will include image recognition technology that another NantWorks company developed to assist the blind.

http://www.labusinessjournal.com/news/2012/jul/24/blackstone-invests-125-million-soon-shiongs-nantph/

-----------------------------------------------------------------------------------------------------------------

ProMetic Life Sciences forms partnership with Blackstone-backed NantPharma

By The Canadian Press | July 30, 2012

 

MONTREAL - ProMetic Life Sciences Inc. (TSX:PLI) and a partner with financial backing from the Blackstone private equity group have formed a joint venture to develop and commercialize a plasma-derived product for the U.S. market.

Under their agreement, ProMetic of Laval, Que., will grant rights to its plasma protein purification system and prion reduction technology to the NantPro BioSciences LLC joint venture.

The other partner, NantPharma LLC, has provided an initial US$2.5 million to NantPro and has the right to make additional capital contributions in exchange for an increased equity stake.

NantPro used the original funds to pay ProMetic for the technology rights and would use additional funds for the development and manufacturing costs of the plasma-derived biopharmaceutical product.

ProMetic will produce batches of the product at Laval plant to enable filing with regulatory filings and, fillowing approval from the U.S. Food and Drug Administration, will make the drugs require for clinical trials.

NantPharma expects to do the final manufacturing steps at its new plant in Terre Haute, Indiana., which will focus on critical care injectable and oncological drugs

NantPharma, which manufacturer products at various locations in the United States, recently received a US$125 million investment for the Terre Haute plant from Blackstone, one of the largest investment groups in the United States.

ProMetic shares closed Friday at 13 cents per share, giving the company a market value of about $56 million.

http://www.canadianbusiness.com/article/93278--prometic-life-sciences-forms-partnership-with-blackstone-backed-nantpharma

-----------------

that guy Bidou = spammer or on bids, do your dd. PLI has now powerful friends... Blackstone... Dr Soon-Shiong that owns 9% of PLI + insiders bought again.

pay back is potentially huge for this stock, may take 3-6 months or 1 year but PLi with the deals signed and its income growth will eventually trade 1$+...

As of 11:59pm ET September 25th, 2012
Filing
Date Transaction
Date Insider Name Ownership
Type Securities Nature of transaction # or value acquired or disposed of Price


Sep 19/12 Sep 19/12 Dumais, Frédéric Indirect Ownership Common Shares 10 - Acquisition in the public market 25,000
.130
Aug 15/12 Aug 15/12 Anthony, G.F. Kym Indirect Ownership Common Shares 10 - Acquisition in the public market 100,000
.145
Jul 19/12 Jul 18/12 Wygodny, Benjamin Indirect Ownership Common Shares 11 - Acquisition carried out privately 249,315
.120
Jul 19/12 Jul 18/12 Wygodny, Benjamin Indirect Ownership Common Shares 11 - Acquisition carried out privately 122,431
.120
Filing
Date Transaction
Date Insider Name Ownership
Type Securities Nature of transaction # or value acquired or disposed of Unit
Price
May 22/12 May 22/12 Pritchard, Bruce Indirect Ownership Common Shares 10 - Acquisition in the public market 144,000
.125
May 22/12 May 22/12 Pritchard, Bruce Indirect Ownership Common Shares 10 - Acquisition in the public market 56,000
.130
May 10/12 May 9/12 Liguori, Diane Lawrence Direct Ownership Options 00 - Opening Balance-Initial SEDI Report
Apr 27/12 Apr 26/12 Wygodny, Benjamin Indirect Ownership Common Shares 11 - Acquisition carried out privately 1,251,141
.135
Apr 27/12 Apr 26/12 Wygodny, Benjamin Indirect Ownership Common Shares 11 - Acquisition carried out privately 518,721
.135
Apr 19/12 Apr 17/12 Wygodny, Benjamin Direct Ownership Warrants 11 - Acquisition carried out privately 454,545
.180
Apr 19/12 Apr 17/12 Wygodny, Benjamin Direct Ownership Common Shares 11 - Acquisition carried out privately 1,136,363
.110
Mar 30/12 Mar 30/12 Dumais, Frédéric Indirect Ownership Common Shares 10 - Acquisition in the public market 50,000
.110

i would only add this to prove PLI is more than on track.

The Corporation confirmed that all remaining forecasted orders previously included in its original 2012 projected $21 million base case business have been secured during the second quarter of 2012. Altogether, during the second quarter, ProMetic confirmed a total of $12.1 million of purchase orders and contracts related to its proprietary affinity adsorbents, and secured two large strategic deals for plasma-derived therapeutics contributing in excess of $4.5 million in 2012 and significantly more in future years.

read q2: http://www.stockhouse.com/companies/stories/t.pli/8587958

They got all revenues projected in 2012 already... with still 3 months to go....

 

Rate this post
0 stars
v
Usefulness

Clarity

Credibility